Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation

OncoImmunology

Volumn 4, Issue 11, 2015, Pages 1-11

  de Haar, Colin ^a   Plantinga, Maud ^a   Blokland, Nina J G ^a   van Til, Niek P ^a   Flinsenberg, Thijs W H ^a   Van Tendeloo, Viggo F ^b   Smits, Evelien L ^b,c   Boon, Louis ^d   Spel, Lotte ^a   Boes, Marianne ^a   Boelens, Jaap Jan ^a   Nierkens, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d BIOCEROS   (Netherlands)

Author keywords

cord blood; dendritic cells; transplantation; vaccination; WT1

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN PRESENTATION; ARTICLE; CD34 SELECTION; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; ELECTROPORATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MIXED LYMPHOCYTE REACTION; NEPHROBLASTOMA; PROTEIN EXPRESSION; RNA TRANSCRIPTION; SIGNAL PROCESSING; VACCINATION;

EID: 84941789191     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1023973     Document Type: Article

References (46)

1. J.-H.Klusmann, D.Reinhardt, M.Zimmermann, B.Kremens, J.Vormoor, M.Dworzak, U.Creutzig, T.Klingebiel. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97:21-9; PMID:21933851; http://dx.doi.org/10.3324/haematol.2011.051714
2. R.Beier, M.H.Albert, P.Bader, A.Borkhardt, U.Creutzig, M.Eyrich, K.Ehlert, B.Gruhn, J.Greil, R.Handgretinger et al. Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplant 2013; 48:651-6; PMID:23103678; http://dx.doi.org/10.1038/bmt.2012.204
3. A.Sander, M.Zimmermann, M.Dworzak, G.Fleischhack, C.Neuhoff von, D.Reinhardt, G.J.L.Kaspers, U.Creutzig. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24:1422-8; PMID:20535146; http://dx.doi.org/10.1038/leu.2010.127
4. M.Eapen, P.Rubinstein, M.-J.Zhang, C.Stevens, J.Kurtzberg, A.Scaradavou, F.R.Loberiza, R.E.Champlin, J.P.Klein, M.M.Horowitz et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. The Lancet 2007; 369:1947-54; PMID:17560447; http://dx.doi.org/10.1016/S0140-6736(07)60915-5
5. G.J.L.Kaspers, M.Zimmermann, D.Reinhardt, B.E.S.Gibson, R.Y.J.Tamminga, O.Aleinikova, H.Armendariz, M.Dworzak, S.Y.Ha, H.Hasle et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group. J Clin Oncol 2013; 31:599-607; PMID:23319696; http://dx.doi.org/10.1200/JCO.2012.43.7384
6. H.Levenga, N.Schaap, F.Maas, B.Esendam, H.Fredrix, A.Greupink-Draaisma, T.de Witte, H.Dolstra, R.Raymakers. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010; 16:320-32; PMID:19835972; http://dx.doi.org/10.1016/j.bbmt.2009.10.006
7. A.P.Rapoport, N.A.Aqui, E.A.Stadtmauer, D.T.Vogl, H.-B.Fang, L.Cai, S.Janofsky, A.Chew, J.Storek, G.Akpek et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011; 117:788-97; PMID:21030558; http://dx.doi.org/10.1182/blood-2010-08-299396
8. G.Frumento, Y.Zheng, G.Aubert, M.Raeiszadeh, P.M.Lansdorp, P.Moss, S.P.Lee, F.E.Chen. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant 2013; 13:45-55; PMID:23016879; http://dx.doi.org/10.1111/j.1600-6143.2012.04286.x
9. E.P.Alyea, D.J.DeAngelo, J.Moldrem, J.M.Pagel, D.Przepiorka, M.Sadelin, J.W.Young, S.Giralt, M.Bishop, S.Riddell. NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010; 16:1037-69; PMID:20580849; http://dx.doi.org/10.1016/j.bbmt.2010.05.005
10. C.G.Brunstein, J.A.Gutman, D.J.Weisdorf, A.E.Woolfrey, T.E.DeFor, T.A.Gooley, M.R.Verneris, F.R.Appelbaum, J.E.Wagner, C.Delaney. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116:4693-9; PMID:20686119; http://dx.doi.org/10.1182/blood-2010-05-285304
11. M.Kapp, S.Stevanović, K.Fick, S.M.Tan, J.Loeffler, A.Opitz, T.Tonn, G.Stuhler, H.Einsele, G.U.Grigoleit. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant 2009; 43:399-410; PMID:19139738; http://dx.doi.org/10.1038/bmt.2008.426
12. J.J.van Rood, C.E.Stevens, J.Smits, C.Carrier, C.Carpenter, A.Scaradavou. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci USA 2009; 106:19952-7; PMID:19901324; http://dx.doi.org/10.1073/pnas.0910310106
13. W.J.Burlingham, J.L.Nelson. Microchimerism in cord blood: mother as anticancer drug. Proc Natl Acad Sci USA 2012; 109:2190-1; PMID:22323582; http://dx.doi.org/10.1073/pnas.1120857109
14. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
15. J.Tel, E.H.J.G.Aarntzen, T.Baba, G.Schreibelt, B.M.Schulte, D.Benitez-Ribas, O.C.Boerman, S.Croockewit, W.J.G.Oyen, M.van Rossum et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Research 2013; 73:1063-75; PMID:23345163; http://dx.doi.org/10.1158/0008-5472.CAN-12-2583
16. V.F.van Tendeloo, A.Van de Velde, A.Van Driessche, N.Cools, S.Anguille, K.Ladell, E.Gostick, K.Vermeulen, K.Pieters, G.Nijs et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/pnas.1008051107
17. S.Balan, V.P.Kale, L.S.Limaye. A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells. Transfusion 2009; 49:2109-21; PMID:18774963; http://dx.doi.org/10.1111/j.1537-2995.2009.02231.x
18. M.A.Cheever, J.P.Allison, A.S.Ferris, O.J.Finn, B.M.Hastings, T.T.Hecht, I.Mellman, S.A.Prindiville, J.L.Viner, L.M.Weiner et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
19. H.D.Menssen, H.J.Renkl, U.Rodeck, J.Maurer, M.Notter, S.Schwartz, R.Reinhardt, E.Thiel. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9:1060-7; PMID:7596170
20. A.Van Driessche, A.L.R.Van de Velde, G.Nijs, T.Braeckman, B.Stein, J.M.De Vries, Z.N.Berneman, V.F.I.Van Tendeloo. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009; 11:653-68; PMID:19530029; http://dx.doi.org/10.1080/14653240902960411
21. G.Cohen, S.L.Carter, K.I.Weinberg, B.Masinsin, E.Guinan, J.Kurtzberg, J.E.Wagner, N.A.Kernan, R.Parkman. Antigen-specific T-lymphocyte function after cord blood transplantation. Biol Blood Marrow Transplant 2006; 12:1335-42; PMID:16399583; http://dx.doi.org/10.1016/j.bbmt.2006.08.036
22. R.Chiesa, K.Gilmour, W.Qasim, S.Adams, A.J.J.Worth, H.Zhan, C.A.Montiel-Equihua, S.Derniame, C.Cale, K.Rao et al. Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012; 156:656-66; PMID:22224700; http://dx.doi.org/10.1111/j.1365-2141.2011.08994.x
23. A.Lanzavecchia. Mechanisms of antigen uptake for presentation. Curr Opin Immunol 1996; 8:348-54; PMID:8794000; http://dx.doi.org/10.1016/S0952-7915(96)80124-5
24. H.Jonuleit, U.Kühn, G.Müller, K.Steinbrink, L.Paragnik, E.Schmitt, J.Knop, A.H.Enk. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135-42; PMID:9464798; http://dx.doi.org/10.1002/eji.1830271209
25. C.Rieser, G.Böck, H.Klocker, G.Bartsch, M.Thurnher. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 1997; 186:1603-8; PMID:9348319; http://dx.doi.org/10.1084/jem.186.9.1603
26. D.Vremec, M.O'Keeffe, A.Wilson, I.Ferrero, U.Koch, F.Radtke, B.Scott, P.Hertzog, J.Villadangos, K.Shortman. Factors determining the spontaneous activation of splenic dendritic cells in culture. Innate Immun 2011; 17:338-52; PMID:20501515; http://dx.doi.org/10.1177/1753425910371396
27. W.Hobo, T.I.Novobrantseva, H.Fredrix, J.Wong, S.Milstein, H.Epstein-Barash, J.Liu, N.Schaap, R.Voort, H.Dolstra. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 2013; 62:285-97; PMID:22903385; http://dx.doi.org/10.1007/s00262-012-1334-1
28. A.W.Lee, T.Truong, K.Bickham, J.-F.Fonteneau, M.Larsson, I.Da Silva, S.Somersan, E.K.Thomas, N.Bhardwaj. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002; 20 Suppl 4:A8-A22; PMID:12477423; http://dx.doi.org/10.1016/S0264-410X(02)00382-1
29. B.Beck, D.Dörfel, F.S.Lichtenegger, C.Geiger, L.Lindner, M.Merk, D.J.Schendel, M.Subklewe. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J Transl Med 2011; 9:151; PMID:21910911; http://dx.doi.org/10.1186/1479-5876-9-151
30. S.Ugel, F.Delpozzo, G.Desantis, F.Papalini, F.Simonato, N.Sonda, S.Zilio, V.Bronte. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9:470-81; PMID:19269896; http://dx.doi.org/10.1016/j.coph.2009.06.014
31. P.C.Rodriguez, M.S.Ernstoff, C.Hernandez, M.Atkins, J.Zabaleta, R.Sierra, A.C.Ochoa. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69:1553-60; PMID:19201693; http://dx.doi.org/10.1158/0008-5472.CAN-08-1921
32. A.Van Driessche, L.Gao, H.J.Stauss, P.Ponsaerts, D.R.Van Bockstaele, Z.N.Berneman, V.F.I.Van Tendeloo. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19:1863-71; PMID:16121214; http://dx.doi.org/10.1038/sj.leu.2403930
33. L.F.Poulin, M.Salio, E.Griessinger, F.Anjos-Afonso, L.Craciun, J.L.Chen, A.M.Keller, O.Joffre, S.Zelenay, E.Nye et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1261-71; PMID:20479117; http://dx.doi.org/10.1084/jem.20092618
34. K.M.Harris. Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukocyte Biol 2011; 90:727-34; PMID:21724805; http://dx.doi.org/10.1189/jlb.0311132
35. S.Anguille, E.Lion, J.Tel, I.J.M.de Vries, K.Couderé, P.D.Fromm, V.F.van Tendeloo, E.L.Smits, Z.N.Berneman. Interleukin-15-induced CD56+ myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One 2012; 7:e51851; PMID:23284789; http://dx.doi.org/10.1371/journal.pone.0051851
36. M.Relloso, A.Puig-Kröger, O.M.Pello, J.L.Rodríguez-Fernández, G.la Rosa de, N.Longo, J.Navarro, M.A.Muñoz-Fernández, P.Sánchez-Mateos, A.L.Corbí. DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and anti-inflammatory agents. J Immunol 2002; 168:2634-43; PMID:11884427; http://dx.doi.org/10.4049/jimmunol.168.6.2634
37. A.Encabo, P.Solves, E.Mateu, P.Sepúlveda, F.Carbonell-Uberos, M.D.Minana. Selective generation of different dendritic cell precursors from CD34+ cells by interleukin-6 and interleukin-3. Stem Cells 2004; 22:725-40; PMID:15342937; http://dx.doi.org/10.1634/stemcells.22-5-725
38. M.Kato, T.K.Neil, D.B.Fearnley, A.D.McLellan, S.Vuckovic, D.N.Hart. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int Immunol 2000; 12:1511-9; PMID:11058570; http://dx.doi.org/10.1093/intimm/12.11.1511
39. S.Nierkens, J.Tel, E.Janssen, G.J.Adema. Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol 2013; 34:361-70; PMID:23540650; http://dx.doi.org/10.1016/j.it.2013.02.007
40. S.Khan, M.S.Bijker, J.J.Weterings, H.J.Tanke, G.J.Adema, T.van Hall, J.W.Drijfhout, C.J.M.Melief, H.S.Overkleeft, G.A.van der Marel et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007; 282:21145-59; PMID:17462991; http://dx.doi.org/10.1074/jbc.M701705200
41. J.Tel, A.J.A.Lambeck, L.J.Cruz, P.J.Tacken, I.J.M.de Vries, C.G.Figdor. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010; 184:4276-83; PMID:20304825; http://dx.doi.org/10.4049/jimmunol.0903286
42. D.Benteyn, S.Anguille, S.Van Lint, C.Heirman, A.M.Van Nuffel, J.Corthals, S.Ochsenreither, W.Waelput, K.Van Beneden, K.Breckpot et al. Design of an optimized Wilms' Tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo. Mol Ther Nucleic Acids 2013; 2:e134; PMID:24253259; http://dx.doi.org/10.1038/mtna.2013.54
43. E.Doubrovina, T.Carpenter, D.Pankov, A.Selvakumar, A.Hasan, R.J.O'Reilly. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias. Blood 2012; 120:1633-46; PMID:22623625; http://dx.doi.org/10.1182/blood-2011-11-394619
44. C.Caux, C.Massacrier, B.Vanbervliet, B.Dubois, I.Durand, M.Cella, A.Lanzavecchia, J.Banchereau. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997; 90:1458-70; PMID:9207440
45. P.Dubsky, H.Saito, M.Leogier, C.Dantin, J.E.Connolly, J.Banchereau, A.K.Palucka. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 2007; 37:1678-90; PMID:17492620; http://dx.doi.org/10.1002/eji.200636329
46. V.F.Van Tendeloo, P.Ponsaerts, F.Lardon, G.Nijs, M.Lenjou, C.Van Broeckhoven, D.R.Van Bockstaele, Z.N.Berneman. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98:49-56; PMID:11418462; http://dx.doi.org/10.1182/blood.V98.1.49